A European clinical trial found that the drug sulthiame significantly reduced breathing interruptions in people with moderate to severe sleep apnea. Patients taking higher doses experienced up to 47% ...

(“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing related sleep disorders and associated chronic health ...

The CGH Sleep Center in Sterling was recognized by the American Academy of Sleep Medicine Board of Directors for 25 consecutive years of accreditation, the organization announced Wednesday. A health ...

Study demonstrates comparable performance between wireless, patch-based Onera Sleep Test System and in-lab polysomnography for sleep staging and respiratory event detection. EINDHOVEN, ...

A large observational study suggests that around seven hours of nightly sleep is associated with lower insulin resistance, while too little or too much sleep may worsen metabolic health.

OSA is a common sleep disorder characterized by oxygen desaturation due to repeated airway collapse during sleep.

More than 80% of patients implanted with a transvenous phrenic nerve stimulation device for central sleep apnea had at least ...

Ryan Hatch has spent his entire life struggling to breathe. “My whole life, I have had trouble breathing through my nose, and ...

A new solution may be on the horizon for the 30 million people in the U.S. who suffer from sleep apnea. In a Finland study, a new breathing device showed promising results in reducing symptoms of the ...

A European clinical trial finds the drug sulthiame can cut breathing interruptions in sleep apnea, offering hope for a ...